SiPhox Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
MIT-founded home blood testing company measuring 17 biomarkers via mail-in kits; Khosla-backed developing photonic chip for instant at-home results competing with Everlywell.
About
SiPhox Health is a home blood testing company founded by MIT scientists that provides mail-in blood test kits measuring 17 key biomarkers — inflammation markers (CRP, homocysteine), cardiovascular health (LDL, HDL, triglycerides, ApoB), metabolic health (HbA1c, glucose, insulin), and hormone levels (testosterone, DHEA, cortisol) — with results delivered within days and integrated with an app for trend tracking and health guidance. Founded in 2020 by Diedrik Vermeulen and Michael Dubrovsky, SiPhox Health is backed by Khosla Ventures, Intel Capital, and Y Combinator.\n\nSiPhox's current product uses at-home finger-prick blood collection with mail-in testing — customers order a $95 kit, collect a small blood sample at home, and mail it to SiPhox's CLIA-certified lab for analysis. The $16/month membership provides regular testing on a quarterly or customizable schedule, enabling biomarker trend monitoring over time rather than single point-in-time snapshots. The underlying technology vision is a photonic chip (silicon photonics-based biosensor) that would enable instant at-home blood analysis without lab processing, with FDA clearance targeted for 2026.\n\nIn 2025, SiPhox Health competes in the home diagnostics and consumer health testing market with Everlywell (the leading at-home test kit brand), Function Health (comprehensive blood panel membership), InsideTracker, and traditional lab companies (LabCorp, Quest Diagnostics) for consumer blood testing. The longevity and proactive health monitoring movement has driven demand for comprehensive biomarker testing beyond what annual physicals provide. The potential photonic chip breakthrough would represent a significant technological leap — enabling truly point-of-care diagnostics without lab infrastructure. The 2025 strategy focuses on growing the biomarker panel subscription business, advancing the photonic chip development toward FDA clearance, and building clinical evidence for the personalized health intervention recommendations.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.